One answer may come from studying the dilution effect and an experiment on drug safety side effects information. On the way there, we need to start with the conventional wisdom in appellate practice.

Palantir's free cash flow grew 70.7% YoY, driven by new revenues and stable capex, outpacing dilution effects. Share dilution is slowing, but option exercises continue, reflecting the ...